Cargando…

Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?

This longitudinal analysis compares the prevalence of depressive symptoms in patients with psoriatic arthritis in the context of the COVID-19 pandemic. Data from a national patient register in Germany were analyzed regarding the Patient Health Questionnaire 2 (PHQ-2) to identify cases suspicious for...

Descripción completa

Detalles Bibliográficos
Autores principales: Englbrecht, Matthias, Bartz-Bazzanella, Peter, von der Decken, Cay, Gauler, Georg, Wurth, Patrick, Aries, Peer, Karberg, Kirsten, Kuhn, Christoph, Schuch, Florian, Späthling-Mestekemper, Susanna, Vorbrüggen, Wolfgang, Wendler, Jörg, Welcker, Martin, Kleinert, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591045/
https://www.ncbi.nlm.nih.gov/pubmed/34790678
http://dx.doi.org/10.3389/fmed.2021.748262
_version_ 1784599129433833472
author Englbrecht, Matthias
Bartz-Bazzanella, Peter
von der Decken, Cay
Gauler, Georg
Wurth, Patrick
Aries, Peer
Karberg, Kirsten
Kuhn, Christoph
Schuch, Florian
Späthling-Mestekemper, Susanna
Vorbrüggen, Wolfgang
Wendler, Jörg
Welcker, Martin
Kleinert, Stefan
author_facet Englbrecht, Matthias
Bartz-Bazzanella, Peter
von der Decken, Cay
Gauler, Georg
Wurth, Patrick
Aries, Peer
Karberg, Kirsten
Kuhn, Christoph
Schuch, Florian
Späthling-Mestekemper, Susanna
Vorbrüggen, Wolfgang
Wendler, Jörg
Welcker, Martin
Kleinert, Stefan
author_sort Englbrecht, Matthias
collection PubMed
description This longitudinal analysis compares the prevalence of depressive symptoms in patients with psoriatic arthritis in the context of the COVID-19 pandemic. Data from a national patient register in Germany were analyzed regarding the Patient Health Questionnaire 2 (PHQ-2) to identify cases suspicious for depression at two time points, i.e., before and during the COVID-19 pandemic. Only patients with complete concurrent information on the Disease Activity in Psoriatic Arthritis Score (DAPSA) were included in the analysis. The frequency of depressive symptoms in psoriatic arthritis patients during the COVID-19 pandemic did not differ from the prevalence rates measured before. In addition, prevalence rates for depressive symptoms did not differ when stratifying the patient sample for DAPSA levels of disease activity measured before the pandemic. These results were confirmed further in a sensitivity analysis, limiting the second PHQ-2 assessment to lockdown periods only. However, longitudinal data on the prevalence of depressive symptoms in patients with rheumatic diseases, in general, and psoriatic arthritis, in particular, are scarce in the context of the COVID-19 pandemic. For a sensible comparison of prevalence rates for depressive symptoms in the future, underlying SARS-CoV-2 infection rates and resulting local healthcare disruptions need to be taken into account, besides the potential use of different depression screening tools to evaluate resulting numbers sensibly and draw corresponding conclusions for patient care.
format Online
Article
Text
id pubmed-8591045
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85910452021-11-16 Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic? Englbrecht, Matthias Bartz-Bazzanella, Peter von der Decken, Cay Gauler, Georg Wurth, Patrick Aries, Peer Karberg, Kirsten Kuhn, Christoph Schuch, Florian Späthling-Mestekemper, Susanna Vorbrüggen, Wolfgang Wendler, Jörg Welcker, Martin Kleinert, Stefan Front Med (Lausanne) Medicine This longitudinal analysis compares the prevalence of depressive symptoms in patients with psoriatic arthritis in the context of the COVID-19 pandemic. Data from a national patient register in Germany were analyzed regarding the Patient Health Questionnaire 2 (PHQ-2) to identify cases suspicious for depression at two time points, i.e., before and during the COVID-19 pandemic. Only patients with complete concurrent information on the Disease Activity in Psoriatic Arthritis Score (DAPSA) were included in the analysis. The frequency of depressive symptoms in psoriatic arthritis patients during the COVID-19 pandemic did not differ from the prevalence rates measured before. In addition, prevalence rates for depressive symptoms did not differ when stratifying the patient sample for DAPSA levels of disease activity measured before the pandemic. These results were confirmed further in a sensitivity analysis, limiting the second PHQ-2 assessment to lockdown periods only. However, longitudinal data on the prevalence of depressive symptoms in patients with rheumatic diseases, in general, and psoriatic arthritis, in particular, are scarce in the context of the COVID-19 pandemic. For a sensible comparison of prevalence rates for depressive symptoms in the future, underlying SARS-CoV-2 infection rates and resulting local healthcare disruptions need to be taken into account, besides the potential use of different depression screening tools to evaluate resulting numbers sensibly and draw corresponding conclusions for patient care. Frontiers Media S.A. 2021-11-01 /pmc/articles/PMC8591045/ /pubmed/34790678 http://dx.doi.org/10.3389/fmed.2021.748262 Text en Copyright © 2021 Englbrecht, Bartz-Bazzanella, von der Decken, Gauler, Wurth, Aries, Karberg, Kuhn, Schuch, Späthling-Mestekemper, Vorbrüggen, Wendler, Welcker and Kleinert. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Englbrecht, Matthias
Bartz-Bazzanella, Peter
von der Decken, Cay
Gauler, Georg
Wurth, Patrick
Aries, Peer
Karberg, Kirsten
Kuhn, Christoph
Schuch, Florian
Späthling-Mestekemper, Susanna
Vorbrüggen, Wolfgang
Wendler, Jörg
Welcker, Martin
Kleinert, Stefan
Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?
title Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?
title_full Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?
title_fullStr Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?
title_full_unstemmed Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?
title_short Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?
title_sort prevalence of depressive symptoms in patients with psoriatic arthritis: have numbers changed during the covid-19 pandemic?
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591045/
https://www.ncbi.nlm.nih.gov/pubmed/34790678
http://dx.doi.org/10.3389/fmed.2021.748262
work_keys_str_mv AT englbrechtmatthias prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT bartzbazzanellapeter prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT vonderdeckencay prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT gaulergeorg prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT wurthpatrick prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT ariespeer prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT karbergkirsten prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT kuhnchristoph prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT schuchflorian prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT spathlingmestekempersusanna prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT vorbruggenwolfgang prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT wendlerjorg prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT welckermartin prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic
AT kleinertstefan prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic